$NTLA News

Intellia Therapeutics (NTLA) Stock Looks Overvalued As Launch Preparations Advance

Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer

Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?

Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8

Intellia Therapeutics Q2 2026 Earnings Call Transcript

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Bears Growl Again, This Time About Claude AI -- Yawn!

Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy

Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances

Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost?

Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13

HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target

Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform

Intellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-z

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)

Intellia Therapeutics Announces FDA Acceptance For Its Biologics License Application For Ionvo-Z; FDA Sets March 10, 2027, As PDUFA Date

Intellia Therapeutics (NTLA) Secures $400 Million As Investors Ask If The Upside Is Priced In

Should Intellia’s Milestone-Linked OrbiMed Loan Reshape Funding Risk Perceptions For Intellia Therapeutics (NTLA) Investors?